Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced adrenocortical carcinoma from the JAVELIN solid tumor phase Ib trial: Safety and clinical activity

被引：1
|
作者：
Le Tourneau, Christophe
Hoimes, Christopher J.
Zarwan, Corrine
Wong, Deborah Jean Lee
Bauer, Sebastian
Wermke, Martin
Claus, Rainer
Chin, Kevin M.
von Heydebreck, Anja
Cuillerot, Jean-Marie
Gulley, James L.
机构：
[1] Inst Curie, Paris, France
[2] Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA
[3] Lahey Clin Fdn, Burlington, MA USA
[4] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA
[5] Univ Hosp, West German Canc Ctr, Essen, Germany
[6] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Dresden, Germany
[7] Univ Klinikum Freiburg, Freiburg, Germany
[8] EMD Serono Inc, Billerica, MA USA
[9] Merck KGaA, Darmstadt, Germany
[10] NCI, Genitourinary Malignancies Branch, Lab Tumor Immunol & Biol, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.4516
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4516
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy.
    Gulley, James L.
    Spigel, David
    Kelly, Karen
    Chandler, Jason Claud
    Rajan, Arun
    Hassan, Raffit
    Wong, Deborah Jean Lee
    Leach, Joseph
    Edenfield, William Jeffery
    Wang, Ding
    Vrindavanam, Nandagopal
    Weiss, Glen J.
    Gurtler, Jayne S.
    Grote, Hans Juergen
    von Heydebreck, Anja
    Chin, Kevin M.
    Iannotti, Nicholas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] A pilot trial of PEGPH20 (Pegvorhyaluronidase alfa) in combination with avelumab (anti-PD-L1 MSB0010718C) in chemotherapy resistant pancreatic cancer (PDAC) - Trial in progress
    Medina Rodriguez, L.
    Guillen-Ponce, C.
    Feliu, J.
    Hidalgo, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [43] Safety and clinical activity of avelumab (MSB0010718C), an anti-programed death-ligand 1 (PD-L1) antibody, in recurrent thymic epithelial tumors (TETs)
    Rajan, Arun
    Chen, Haobin
    Zhao, Chen
    Swift, Shannon
    Mammen, Andrew
    Brofferio, Alessandra
    Padiernos, Emerson
    Szabo, Eva
    Guha, Udayan
    Hassan, Raffit
    Steinberg, Seth
    Tsai, Yo-Ting
    Donahue, Renee
    Schlom, Jeffrey
    Gulley, James
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [44] Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN Gastric 300 trial.
    Bang, Yung-Jue
    Wyrwicz, Lucjan
    Park, Young Lee
    Ryu, Min-Hee
    Muntean, Alina
    Gomez-Martin, Carlos
    Guimbaud, Rosine
    Ciardiello, Fortunato
    Boku, Narikazu
    Van Cutsem, Eric
    Taieb, Julien
    Xiong, Huiling
    Zhang, Jenny
    Cuillerot, Jean-Marie
    Gurtler, Jayne S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] Avelumab (anti-PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): Updated results from the phase Ib JAVELIN solid tumour JPN trial
    Doi, T.
    Iwasa, S.
    Muro, K.
    Satoh, T.
    Hironaka, S.
    Esaki, T.
    Nishina, T.
    Hara, H.
    Machida, N.
    Komatsu, Y.
    Shimada, Y.
    Otsu, S.
    Shimizu, S.
    Chand, V.
    Watanabe, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [46] Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial
    Toshihiko Doi
    Satoru Iwasa
    Kei Muro
    Taroh Satoh
    Shuichi Hironaka
    Taito Esaki
    Tomohiro Nishina
    Hiroki Hara
    Nozomu Machida
    Yoshito Komatsu
    Yasuhiro Shimada
    Satoshi Otsu
    Shin Shimizu
    Morihiro Watanabe
    Gastric Cancer, 2019, 22 : 817 - 827
  • [47] Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial
    Doi, Toshihiko
    Iwasa, Satoru
    Muro, Kei
    Satoh, Taroh
    Hironaka, Shuichi
    Esaki, Taito
    Nishina, Tomohiro
    Hara, Hiroki
    Machida, Nozomu
    Komatsu, Yoshito
    Shimada, Yasuhiro
    Otsu, Satoshi
    Shimizu, Shin
    Watanabe, Morihiro
    GASTRIC CANCER, 2019, 22 (04) : 817 - 827
  • [48] Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
    Luc Y. Dirix
    Istvan Takacs
    Guy Jerusalem
    Petros Nikolinakos
    Hendrik-Tobias Arkenau
    Andres Forero-Torres
    Ralph Boccia
    Marc E. Lippman
    Robert Somer
    Martin Smakal
    Leisha A. Emens
    Borys Hrinczenko
    William Edenfield
    Jayne Gurtler
    Anja von Heydebreck
    Hans Juergen Grote
    Kevin Chin
    Erika P. Hamilton
    Breast Cancer Research and Treatment, 2018, 167 : 671 - 686
  • [49] JAVELIN PARP medley: A phase Ib/II study of avelumab (anti-PD-L1) plus talazoparib in locally advanced or metastatic solid tumors
    Yap, T. A.
    Beck, J. T.
    Stewart, R. A.
    Dahm, S. C.
    Chappey, C.
    Cesari, R.
    Scheuber, A.
    Galsky, M. D.
    Wise, D.
    ANNALS OF ONCOLOGY, 2018, 29 : 441 - 441
  • [50] Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
    Dirix, Luc Y.
    Takacs, Istvan
    Jerusalem, Guy
    Nikolinakos, Petros
    Arkenau, Hendrik-Tobias
    Forero-Torres, Andres
    Boccia, Ralph
    Lippman, Marc E.
    Somer, Robert
    Smakal, Martin
    Emens, Leisha A.
    Hrinczenko, Borys
    Edenfield, William
    Gurtler, Jayne
    von Heydebreck, Anja
    Grote, Hans Juergen
    Chin, Kevin
    Hamilton, Erika P.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (03) : 671 - 686
12345